Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16167735 | 0.80 | SPR (0.52) | SPRGSK3BPDE10APOLB | |
| SCHEMBL12703712 | 0.79 | HSD17B10 (0.46) | SPRGSK3BALDH1A1POLB | |
| SCHEMBL16199065 | 0.79 | HPGD (0.46) | SPRGSK3BALDH1A1POLB | |
| SCHEMBL3026539 | 0.79 | GSK3B (0.43) | SPRGSK3BALDH1A1POLB | |
| SCHEMBL19480629 | 0.79 | GSK3B (0.58) | SPRGSK3BALDH1A1PDE10APOLB | |
| SCHEMBL25527223 | 0.76 | GSK3B (0.38) | SPRGSK3BPDE10APOLBHTR3A | |
| SCHEMBL24331224 | 0.71 | BRD4 (0.50) | GSK3BHTR3A | |
| SCHEMBL14488171 | 0.70 | GRIN1 (0.37) | — | |
| SCHEMBL19230912 | 0.70 | ADORA2A (0.32) | ALDH1A1PDE10A | |
| SCHEMBL3034786 | 0.69 | SPR (0.33) | SPRGSK3BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, DPYD, TYMS | SPR 1342/4885GSK3B 4414/4885ALDH1A1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.